Mostrar el registro sencillo del ítem

dc.contributor.authorContreras Ropero, Jefferson Eduardo
dc.contributor.authorRuiz Roa, Silvia Liliana
dc.contributor.authorGarcía-Martinez, Janet
dc.contributor.authorUrbina-Suarez, Nestor Andres
dc.contributor.authorLópez Barrera, German Luciano
dc.contributor.authorBarajas Solano, andres F
dc.contributor.authorZUORRO, Antonio
dc.date.accessioned2024-04-16T14:08:18Z
dc.date.available2024-04-16T14:08:18Z
dc.date.issued2021-12-24
dc.identifier.urihttps://repositorio.ufps.edu.co/handle/ufps/6933
dc.description.abstractThe production of vaccines of biological origin presents a tremendous challenge for researchers. In this context, animal cell cultures are an excellent alternative for the isolation and production of biologicals against several viruses, since they have an affinity with viruses and a great capacity for their replicability. Different variables have been studied to know the system’s ideal parameters, allowing it to obtain profitable and competitive products. Consequently, this work focuses its efforts on evaluating an alternative for producing an anti-influenza biological from MDCK cells using SuperPro Designer v8.0 software. The process uses the DMEN culture medium supplemented with nutrients as raw material for cell development; the MDCK cells were obtained from a potential scale-up with a final working volume of 500 L, four days of residence time, inoculum volume of 10%, and continuous working mode with up to a total of 7400 h/Yr of work. The scheme has the necessary equipment for the vaccine’s production, infection, and manufacture with yields of up to 416,698 units/h. In addition, it was estimated to be economically viable to produce recombinant vaccines with competitive prices of up to 0.31 USD/unit.eng
dc.format.extent9 Páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherApplied Sciences (Switzerland)spa
dc.relation.ispartofAppl. Sci. 2022, 12, 183. https://doi.org/ 10.3390/app12010183
dc.rightsunder the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).eng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/spa
dc.sourcehttps://www.mdpi.com/2076-3417/12/1/183spa
dc.titleA Simulation Analysis of an Influenza Vaccine Production Plant in Areas of High Humanitarian Flow. A Preliminary Study for the Region of Norte de Santander (Colombia)eng
dc.typeArtículo de revistaspa
dcterms.referencesReed, C.; Chaves, S.S.; Kirley, P.D.; Emerson, R.; Aragon, D.; Hancock, E.B.; Butler, L.; Baumbach, J.; Hollick, G.; Bennett, N.M.; et al. Estimating Influenza Disease Burden from Population-Based Surveillance Data in the United States. PLoS ONE 2015, 10, e0118369. [CrossRef] [PubMed]spa
dcterms.referencesInstituto Nacional de Salud. Acute Respiratory Infection Event Report, Colombia, 2019. Available online: https://www.ins.gov.co/ buscador-eventos/Informesdeevento/INFECCIÓN%20RESPIRATORIA%20AGUDA_2019.pdf (accessed on 11 September 2021).spa
dcterms.referencesInternational Organization for Migration. DTM Survey—Vocation of Venezuelan Population to Stay in Colombia, Colombia, 2020. Available online: https://colombia.iom.int/sites/colombia/files/EYE/Vocacion/INFORME%20DTM%20VILLA%20DEL%20 ROSARIO.pdf (accessed on 10 December 2021).spa
dcterms.referencesMinisterio de Salud y Protección Social de Colombia. Ten-Year Public Health Plan 2012–2021 of Colombia. 2012. Available online: https://www3.paho.org/hq/index.php?option=com_content&view=article&id=8777:2013-plan-decenal-salud-publica2012-2021-colombia&Itemid=40264&lang=es (accessed on 11 September 2021).spa
dcterms.referencesMinisterio de Salud y Protección Social de Colombia. ABC of the Ten-Year Public Health Plan. Available online: https: //www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/PSP/IMP_4feb+ABCminsalud.pdf (accessed on 11 September 2021).spa
dcterms.referencesInstituto Departamental de Salud de Norte de Santander. Health Situation Analysis with the Social Determinants Model Norte de Santander Department 2019, Colombia. 2019. Available online: https://ids.gov.co/web/2020/TRANSPARENCIA/ASIS_ DPTAL_NTE%20SDER_2019_ABRIL_2020.pdf (accessed on 10 December 2021).spa
dcterms.referencesAthimulam, A.; Kumaresan, S.; Foo, D.; Sarmidi, M.; Aziz, R. Modelling and Optimization of Eurycoma longifolia Water Extract Production. Food Bioprod. Process. 2006, 84, 139–149. [CrossRef]spa
dcterms.referencesSparrow, E.; Wood, J.G.; Chadwick, C.; Newall, A.T.; Torvaldsen, S.; Moen, A.; Torelli, G. Global production capacity of seasonal and pandemic influenza vaccines in 2019. Vaccine 2021, 39, 512–520. [CrossRef] [PubMed]spa
dcterms.referencesJiang, B.; Patel, M.; Glass, R.I. Polio endgame: Lessons for the global rotavirus vaccination program. Vaccine 2019, 37, 3040–3049. [CrossRef]spa
dcterms.referencesCanizales, L.; Rojas, F.; Pizarro, C.A.; Caicedo-Ortega, N.H.; Villegas-Torres, M.F. SuperPro Designer®, User-Oriented Software Used for Analyzing the Techno-Economic Feasibility of Electrical Energy Generation from Sugarcane Vinasse in Colombia. Processes 2020, 8, 1180. [CrossRef]spa
dcterms.referencesErnst, S.; Garro, O.A.; Winkler, S.; Venkataraman, G.; Langer, R.; Cooney, C.L.; Sasisekharan, R. Process simulation for recombinant protein production: Cost estimation and sensitivity analysis for heparinase I expressed in Escherichia coli. Biotechnol. Bioeng. 1997, 53, 575–582. [CrossRef]spa
dcterms.referencesHuang, D.; Xia-Hou, K.; Liu, X.-P.; Zhao, L.; Fan, L.; Ye, Z.; Tan, W.-S.; Luo, J.; Chen, Z. Rational design of medium supplementation strategy for improved influenza viruses production based on analyzing nutritional requirements of MDCK Cells. Vaccine 2014, 32, 7091–7097. [CrossRef]spa
dcterms.referencesGenzel, Y. Designing cell lines for viral vaccine production: Where do we stand? Biotechnol. J. 2015, 10, 728–740. [CrossRef]spa
dcterms.referencesLi, I.; Chan, K.; To, K.; Wong, S.; Ho, P.L.; Lau, S.K.P.; Woo, P.C.Y.; Tsoi, H.; Chan, J.F.-W.; Cheng, V.; et al. Differential susceptibility of different cell lines to swine-origin influenza A H1N1, seasonal human influenza A H1N1, and avian influenza A H5N1 viruses. J. Clin. Virol. 2009, 46, 325–330. [CrossRef]spa
dcterms.referencesFontana, D.; Marsili, F.; Garay, E.; Battagliotti, J.; Etcheverrigaray, M.; Kratje, R.; Prieto, C. A simplified roller bottle platform for the production of a new generation VLPs rabies vaccine for veterinary applications. Comp. Immunol. Microbiol. Infect. Dis. 2019, 65, 70–75. [CrossRef]spa
dcterms.referencesDewannieux, M.; Ribet, D.; Heidmann, T. Risks linked to endogenous retroviruses for vaccine production: A general overview. Biologicals 2010, 38, 366–370. [CrossRef]spa
dcterms.referencesGeorge, M.; Farooq, M.; Dang, T.; Cortes, B.; Liu, J.; Maranga, L. Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process. Biotechnol. Bioeng. 2010, 106, 906–917. [CrossRef]spa
dcterms.referencesLimonta, M.; Krajnc, N.L.; Vidiˇc, U.; Zumalacárregui, L. Simulation for the recovery of plasmid for a DNA vaccine. Biochem. Eng. J. 2013, 80, 14–18. [CrossRef]spa
dcterms.referencesPetrides, D.; Carmichael, D.; Siletti, C.; Koulouris, A. Biopharmaceutical Process Optimization with Simulation and Scheduling Tools. Bioengineering 2014, 1, 154. [CrossRef]spa
dcterms.referencesLiu, J.; Mani, S.; Schwartz, R.; Richman, L.; Tabor, D.E. Cloning and assessment of tumorigenicity and oncogenicity of a Madin–Darby canine kidney (MDCK) cell line for influenza vaccine production. Vaccine 2010, 28, 1285–1293. [CrossRef]spa
dcterms.referencesGuerriero, V. Power Law Distribution: Method of Multi-Scale Inferential Statistics. J. Mod. Math. Front. JMMF 2012, 1, 21–28.spa
dcterms.referencesYouil, R.; Su, Q.; Toner, T.; Szymkowiak, C.; Kwan, W.-S.; Rubin, B.; Petrukhin, L.; Kiseleva, I.; Shaw, A.; DiStefano, D. Comparative study of influenza virus replication in Vero and MDCK cell lines. J. Virol. Methods 2004, 120, 23–31. [CrossRef]spa
dcterms.referencesValero, Y.; Olveira, J.; López-Vázquez, C.; Dopazo, C.; Bandín, I. BEI Inactivated Vaccine Induces Innate and Adaptive Responses and Elicits Partial Protection upon Reassortant Betanodavirus Infection in Senegalese Sole. Vaccines 2021, 9, 458. [CrossRef]spa
dcterms.referencesMoyle, P.M. Progress in Vaccine Development. Curr. Protoc. Microbiol. 2015, 36, 18.1.1–18.1.26. [CrossRef]spa
dcterms.referencesFrey, S.; Vesikari, T.; Szymczakiewicz-Multanowska, A.; Lattanzi, M.; Izu, A.; Groth, N.; Holmes, S. Clinical Efficacy of Cell Culture–Derived and Egg-Derived Inactivated Subunit Influenza Vaccines in Healthy Adults. Clin. Infect. Dis. 2010, 51, 997–1004. [CrossRef]spa
dcterms.referencesBart, S.; Cannon, K.; Herrington, D.; Mills, R.; Forleo-Neto, E.; Lindert, K.; Mateen, A.A. Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study. Hum. Vaccines Immunother. 2016, 12, 2278–2288. [CrossRef]spa
dcterms.referencesHartvickson, R.; Cruz, M.; Ervin, J.; Brandon, D.; Forleo-Neto, E.; Dagnew, A.F.; Chandra, R.; Lindert, K.; Mateen, A.A. Noninferiority of mammalian cell-derived quadrivalent subunit influenza virus vaccines compared to trivalent subunit influenza virus vaccines in healthy children: A phase III randomized, multicenter, double-blind clinical trial. Int. J. Infect. Dis. 2015, 41, 65–72. [CrossRef]spa
dcterms.referencesAmbrozaitis, A.; Groth, N.; Bugarini, R.; Sparacio, V.; Podda, A.; Lattanzi, M. A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine. Vaccine 2009, 27, 6022–6029. [CrossRef]spa
dcterms.referencesSzymczakiewicz-Multanowska, A.; Groth, N.; Bugarini, R.; Lattanzi, M.; Casula, D.; Hilbert, A.; Tsai, T.; Podda, A. Safety and Immunogenicity of a Novel Influenza Subunit Vaccine Produced in Mammalian Cell Culture. J. Infect. Dis. 2009, 200, 841–848. [CrossRef]spa
dcterms.referencesMinisterio de Salud y Protección Social de Colombia. Guidelines for the Management and Administration of the Expanded Program on Immunization—API—2020, Colombia, 2020. Available online: https://www.minsalud.gov.co/sites/rid/Lists/ BibliotecaDigital/RIDE/VS/PP/ET/lineamientos-nacionales-pai2020.pdf (accessed on 10 December 2021).spa
dcterms.referencesAliya Mohamad Ros, F.N.; Rahman, N.A.; Ali, J.M.; Anuar, N.; Abdullah, S.R.B.S.; Yusoff, A.F.B.J. Comparative Study between Avian Cell and Mammalian Cell in Production of Influenza Vaccine Shariah Compliance. IOP Conf. Series Mater. Sci. Eng. 2020, 778, 12029. [CrossRef]spa
dcterms.referencesFarid, S.S. Process economics of industrial monoclonal antibody manufacture. J. Chromatogr. B 2007, 848, 8–18. [CrossRef]spa
dcterms.referencesNestola, P.; Peixoto, C.; Silva, R.R.J.S.; Alves, P.M.; Mota, J.P.B.; Carrondo, M.J.T. Improved virus purification processes for vaccines and gene therapy. Biotechnol. Bioeng. 2015, 112, 843–857. [CrossRef]spa
dcterms.referencesYang, W.C.; Lu, J.; Kwiatkowski, C.; Yuan, H.; Kshirsagar, R.; Ryll, T.; Huang, Y.-M. Perfusion Seed Cultures Improve Biopharmaceutical Fed-Batch Production Capacity and Product Quality. Biotechnol. Prog. 2014, 30, 616–625. [CrossRef]spa
dcterms.referencesTapia, F.; Vázquez-Ramírez, D.; Genzel, Y.; Reichl, U. Bioreactors for high cell density and continuous multi-stage cultivations: Options for process intensification in cell culture-based viral vaccine production. Appl. Microbiol. Biotechnol. 2016, 100, 2121–2132. [CrossRef]spa
dcterms.referencesXu, J.; Xu, X.; Huang, C.; Angelo, J.; Oliveira, C.L.; Xu, M.; Xu, X.; Temel, D.; Ding, J.; Ghose, S.; et al. Biomanufacturing evolution from conventional to intensified processes for productivity improvement: A case study. MAbs 2020, 12, 1770669. [CrossRef]spa
dcterms.referencesRubio, A.P.; Eiros, J.M. Cell culture-derived flu vaccine: Present and future. Hum. Vaccines Immunother. 2018, 14, 1874–1882. [CrossRef] [PubMed]spa
dcterms.referencesLee, B.Y.; Connor, D.L.; Wateska, A.R.; Norman, B.A.; Rajgopal, J.; Cakouros, B.E.; Chen, S.-I.; Claypool, E.G.; Haidari, L.A.; Karir, V.; et al. Landscaping the structures of GAVI country vaccine supply chains and testing the effects of radical redesign. Vaccine 2015, 33, 4451–4458. [CrossRef] [PubMed]spa
dcterms.referencesChen, S.-I.; Norman, B.A.; Rajgopal, J.; Assi, T.M.; Lee, B.Y.; Brown, S. A planning model for the WHO-EPI vaccine distribution network in developing countries. IIE Trans. 2014, 46, 853–865. [CrossRef]spa
dcterms.referencesHaidari, L.A.; Connor, D.L.; Wateska, A.R.; Brown, S.T.; Mueller, L.E.; Norman, B.A.; Schmitz, M.M.; Paul, P.; Rajgopal, J.; Welling, J.S.; et al. Augmenting Transport versus Increasing Cold Storage to Improve Vaccine Supply Chains. PLoS ONE 2013, 8, e64303. [CrossRef]spa
dcterms.referencesLemmens, S.; Decouttere, C.; Vandaele, N.; Bernuzzi, M. A review of integrated supply chain network design models: Key issues for vaccine supply chains. Chem. Eng. Res. Des. 2016, 109, 366–384. [CrossRef]spa
dc.identifier.doihttps://doi.org/10.3390/app12010183
dc.relation.citationeditionVol.12 No.183 (2022)spa
dc.relation.citationendpage9spa
dc.relation.citationissue183.(2022)spa
dc.relation.citationstartpage1spa
dc.relation.citationvolume12spa
dc.relation.citesContreras-Ropero, J.E.; Ruiz-Roa, S.L.; García-Martínez, J.B.; Urbina-Suarez, N.A.; López-Barrera, G.L.; Barajas-Solano, A.F.; Zuorro, A. A Simulation Analysis of an Influenza Vaccine Production Plant in Areas of High Humanitarian Flow. A Preliminary Study for the Region of Norte de Santander (Colombia). Appl. Sci. 2022, 12, 183. https://doi.org/ 10.3390/app12010183
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.creativecommonsAtribución 4.0 Internacional (CC BY 4.0)spa
dc.subject.proposalmodeling processeng
dc.subject.proposalSuperPro Designer®eng
dc.subject.proposalcell cultureeng
dc.subject.proposalpublic healtheng
dc.subject.proposaldeveloping countrieseng
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.redcolhttp://purl.org/redcol/resource_type/ARTspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
Excepto si se señala otra cosa, la licencia del ítem se describe como under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).